Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

201 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Rapid viral rebound after analytical treatment interruption in patients with very small HIV reservoir and minimal on-going viral transcription.
Pannus P, Rutsaert S, De Wit S, Allard SD, Vanham G, Cole B, Nescoi C, Aerts J, De Spiegelaere W, Tsoumanis A, Couttenye MM, Herssens N, De Scheerder MA, Vandekerckhove L, Florence E. Pannus P, et al. Among authors: vanham g. J Int AIDS Soc. 2020 Feb;23(2):e25453. doi: 10.1002/jia2.25453. J Int AIDS Soc. 2020. PMID: 32107887 Free PMC article.
Qualitative plasma viral load determination as a tool for screening of viral reservoir size in PWH.
Laeremans T, D'haese S, Aernout J, Barbé K, Pannus P, Rutsaert S, Vancutsem E, Vanham G, Necsoi C, Spiegelaere W, Couttenye M, Herssens N, Scheerder MA, Wit S, Vandekerckhove L, Florence E, Aerts JL, Allard SD. Laeremans T, et al. Among authors: vanham g. AIDS. 2022 Nov 1;36(13):1761-1768. doi: 10.1097/QAD.0000000000003352. Epub 2022 Aug 10. AIDS. 2022. PMID: 36172869
iHIVARNA phase IIa, a randomized, placebo-controlled, double-blinded trial to evaluate the safety and immunogenicity of iHIVARNA-01 in chronically HIV-infected patients under stable combined antiretroviral therapy.
de Jong W, Aerts J, Allard S, Brander C, Buyze J, Florence E, van Gorp E, Vanham G, Leal L, Mothe B, Thielemans K, Plana M, Garcia F, Gruters R; iHIVARNA consortium. de Jong W, et al. Among authors: vanham g. Trials. 2019 Jun 17;20(1):361. doi: 10.1186/s13063-019-3409-1. Trials. 2019. PMID: 31208472 Free PMC article. Clinical Trial.
Therapeutic Vaccine in Chronically HIV-1-Infected Patients: A Randomized, Double-Blind, Placebo-Controlled Phase IIa Trial with HTI-TriMix.
Jong W, Leal L, Buyze J, Pannus P, Guardo A, Salgado M, Mothe B, Molto J, Moron-Lopez S, Gálvez C, Florence E, Vanham G, Gorp EV, Brander C, Allard S, Thielemans K, Martinez-Picado J, Plana M, García F, Gruters RA. Jong W, et al. Among authors: vanham g. Vaccines (Basel). 2019 Dec 6;7(4):209. doi: 10.3390/vaccines7040209. Vaccines (Basel). 2019. PMID: 31817794 Free PMC article.
CD32+CD4+ memory T cells are enriched for total HIV-1 DNA in tissues from humanized mice.
Adams P, Fievez V, Schober R, Amand M, Iserentant G, Rutsaert S, Dessilly G, Vanham G, Hedin F, Cosma A, Moutschen M, Vandekerckhove L, Seguin-Devaux C. Adams P, et al. Among authors: vanham g. iScience. 2020 Nov 30;24(1):101881. doi: 10.1016/j.isci.2020.101881. eCollection 2021 Jan 22. iScience. 2020. PMID: 33364576 Free PMC article.
201 results